We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Hsv 1 and 2 Gowey Protocol Versus Placebo

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01477879
Recruitment Status : Completed
First Posted : November 23, 2011
Last Update Posted : November 23, 2011
Sponsor:
Information provided by (Responsible Party):
Dr. Brandie Gowey, NMD, Naturopaths International

Brief Summary:
This study will compare efficacy of versabase gel with 20% sarracenia purpurea versus placebo applied every 3-4 hours to herpes lesions.

Condition or disease Intervention/treatment Phase
Herpes Other: Versabase gel with sarracenia purpurea 20% liquid extract Other: placebo (versabase gel only) Phase 1 Phase 2

Detailed Description:
Patients screened for hsv one or two. Patients with herpes given a 1/8 oz of gel. Researcher does not know which is active and which is placebo (placebo is actually just versabase gel). Patent applies gel to lesions every 3-4 hours. Returns to clinic on days 3, 5, and 14 for evaluation. Up to 50 patients may be enrolled.

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 33 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Phase II Clinical Trial of Versabase/Sarracenia Purpurea Versus Placebo
Study Start Date : January 2011
Primary Completion Date : March 2011
Study Completion Date : March 2011

Arm Intervention/treatment
Active Comparator: Versabase/20% S. purpurea extract Other: Versabase gel with sarracenia purpurea 20% liquid extract
Topical application of gel/plant mix to lesions
Placebo Comparator: placebo (versabase gel only)
placebo used will be versabase gel alone
Other: placebo (versabase gel only)
versabase gel only



Primary Outcome Measures :
  1. Pain [ Time Frame: 2 weeks ]
    Pain scale-- subjective

  2. Size [ Time Frame: 2 weeks ]
    Measure lesion size over 2 weeks


Secondary Outcome Measures :
  1. Appearance [ Time Frame: 2 weeks ]
    Photo taken of lesion w patient informed consent



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

- Hsv 1&2

Exclusion Criteria:

  • No active lesions

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01477879


Locations
United States, Arizona
Naturopaths international
Flagstaff, Arizona, United States, 86001
Sponsors and Collaborators
Naturopaths International

Responsible Party: Dr. Brandie Gowey, NMD, Brandie Gowey, Naturopaths International
ClinicalTrials.gov Identifier: NCT01477879     History of Changes
Other Study ID Numbers: HSV1&2
First Posted: November 23, 2011    Key Record Dates
Last Update Posted: November 23, 2011
Last Verified: November 2011